Zanamivir: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Zanamivir ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[zəˈnæmɪvir]}}) is a [[neuraminidase inhibitor]] used in the treatment of and [[prophylaxis]] of both [[Influenzavirus A]] and [[Influenzavirus B]]. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by [[GlaxoSmithKline]] under the [[trade name]] Relenza. Relenza is the only type of '''Zanamivir'''. | |||
==Category== | ==Category== | ||
Antiviral | Antiviral | ||
==US Brand Names== | ==US Brand Names== | ||
RELENZA<sup>®</sup> | RELENZA<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Zanamivir description|Description]]''' | |||
''' [[Zanamivir description|Description]]''' | |||
'''| [[Zanamivir clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Zanamivir clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Zanamivir microbiology|Microbiology]]''' | '''| [[Zanamivir microbiology|Microbiology]]''' | ||
| Line 28: | Line 32: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Zanamivir is an inhibitor of [[influenza virus]] neuraminidase affecting release of viral particles. | |||
Zanamivir is an inhibitor of [[influenza virus]] [[neuraminidase]] affecting release of viral particles. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Antibiotics]] | ||
[[Category:Wikinfect]] | [[Category:Wikinfect]] | ||
Revision as of 23:50, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Overview
Zanamivir (INN) (IPA: Template:IPA) is a neuraminidase inhibitor used in the treatment of and prophylaxis of both Influenzavirus A and Influenzavirus B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza. Relenza is the only type of Zanamivir.
Category
Antiviral
US Brand Names
RELENZA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Directions For Use | How Supplied | Labels and Packages
Mechanism of Action
Zanamivir is an inhibitor of influenza virus neuraminidase affecting release of viral particles.